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Treatment of advanced colorectal cancer (CRC) increasingly requires a multidisciplinary approach and multiple treatment options
add to the complexity of clinical decision-making. Recently novel targeted therapy against angiogenesis and epidermal growth factor
receptor completed a plethora of phase III studies. The addition of bevacizumab to chemotherapy improved the efficacy over
chemotherapy alone in both first and second line settings, although the magnitude of benefit may not be as great when a more
optimal chemotherapy platform is used. Studies performed thus far did not address conclusively whether bevacizumab should be
continued in subsequent lines of treatment. Anti-angiogenesis tyrosine kinase inhibitors have not shown any additional benefit over
chemotherapy alone so far. Although some benefits were seen with cetuximab in all settings of treating advanced CRC, K-ras
mutation status provides an important determinant of who would not benefit from such a treatment. Caution should be exercised in
combining anti-angiogenesis with anti-EGFR strategy until further randomised data become available. In this review, we have focused
on the implications of these trial results on the everyday management decisions of treating advanced CRC.
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Treatment of advanced colorectal cancer (CRC) increasingly
requires a multidisciplinary approach and multiple treatment
options add to the complexity of clinical decision-making. The
ability to cure some patients with metastasis confined in liver or
lung has also challenged the conventional treatment approach and is
now integrating both systemic treatment and locoregional approach.
Recently novel targeted therapy against angiogenesis and epidermal
growth factor receptor (EGFR) completed a plethora of phase III
studies. In this review, we have focused on the implications of these
trial results on the everyday management decisions of treating
advanced CRC. Furthermore, we have discussed the duration of
treatment; sequential vs combination treatment; treating elderly and
poor performance status patients; oral fluoropyrimidines as well as
management of resectable metastasis.
WHAT IS AN APPROPRIATE PRIMARY END POINT IN
ADVANCED CRC TRIALS?
Improvement in overall survival (OS) has traditionally been
regarded as the most important end point in assessing experi-
mental therapy. Yet reliant on this end point may require many
years of follow-up and may delay the introduction of effective
treatment into routine clinical practice. Furthermore, with effective
post-trial treatment, the beneficial effect of experimental therapy
may be diluted, especially if the experimental therapy is made
available to the trial patients after failing control treatment.
Intermediate end points, in particular progression-free survival
(PFS), have been generally used as a surrogate for OS. Indeed, in a
recent pooled analysis of 39 randomised controlled trials (RCTs) of
first line therapy (Tang et al, 2007), there was a strong relationship
between hazard ratios for PFS and OS. A novel therapy, which
produced a 10% reduction in risk of progression would yield an
estimated 5.4±1% reduction in risk of death. However, reliance on
PFS in assessing a novel treatment effect is not without pitfalls
(Panageas et al, 2007). The date with radiological progression first
evident is often used as a proxy for the true progression, when in
fact the true progression time lies somewhere between this date
and the last radiological assessment date. As a result, the protocol-
specified time interval between radiological assessments used in
clinical trials (for example, every 6 weeks vs every 12 weeks) may
have an impact on the PFS, thus making cross-trial comparisons of
clinical benefits with treatment particularly problematic. In
addition, definition of PFS is also not universal among phase III
trials and this potentially leads to different magnitudes of benefit
from the same agent (for example, bevacizumab) seen in advanced
CRC (Hurwitz et al, 2004; Saltz et al, 2008).
ANGIOGENESIS
Vascular endothelial growth factor (VEGF) represents one of
the most important pro-angiogenic proteins. Bevacizumab is a
humanised monoclonal antibody against VEGF. A series of
randomised studies has initially established and subsequently
refined the role of bevacizumab and anti-angiogenic therapy
as treatment for advanced CRC. Table 1 shows the efficacy results
of these studies (Kabbinavar et al, 2003, 2005a,b; Hurwitz et al,
2004; Giantonio et al, 2007; Hecht et al, 2007, 2009; Kohne et al,
2007; Saltz et al, 2007, 2008; Berry et al, 2008; Cunningham
et al, 2008; Reinacher-Schick et al, 2008; Grothey et al, 2008b;
Tol et al, 2009).
Initially a randomised phase II study compared bolus 5-FU/
leucovorin (LV) alone with 5-FU/LV combined with two different
doses of bevacizumab (5 and 10mgkg
 1 every 2 weeks)
(Kabbinavar et al, 2003). Interestingly, only the lower dose of
bevacizumab (5mgkg
 1) significantly improved the objective
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www.bjcancer.comresponse rate (ORR) and time to tumour progression (TTP) over
chemotherapy alone. As a result, this lower dose was chosen in the
pivotal study, although there is still much debate about the optimal
dose of bevacizumab in solid tumours (Hurwitz et al, 2004; Sandler
et al, 2006; Giantonio et al, 2007; Miller et al, 2007). The pivotal
study showed a significant improvement in ORR, PFS and OS with
the addition of bevacizumab to irinotecan/bolus 5-FU/leucovorin
(IFL) compared to IFL alone (Hurwitz et al, 2004), although it is
now recognised that IFL was not an optimal chemotherapy
platform in advanced CRC (Fuchs et al, 2007). Bevacizumab plus
Table 1 Selected studies evaluating angiogenesis inhibitors in advanced colorectal cancer
Study Treatment arms
Number of
patients
Response
rates (%) P-value
Median
progression-
free survival
(months) P-value
Median
overall
survival
(months) P-value
First line
Kabbinavar et al (2003) 5-FU/LV 36 17 — 5.2 — 13.8 NR
5-FU/LV/BEV (5mg kg
 1) 35 40 0.029 9.0 0.005 21.5 NR
5-FU/LV/BEV (10mg kg
 1) 33 24 0.434 7.2 0.217 16.1 NR
Hurwitz et al (2004) IFL 411 34.8 — 6.2 — 15.6 —
AVF 2107 IFL/BEV 402 44.8 0.004 10.6 o0.001 20.3 o0.001
5-FU/LV/BEV 110 40.0 0.66 8.8 0.4192 18.3 0.2521
Kabbinavar et al (2005b) 5-FU/LV 105 15.2 — 5.5 — 12.9 —
5-FU/LV/BEV 104 26.0 0.055 9.2 0.0002 16.6 0.16
Kabbinavar et al (2005a) 5-FU/LV or IFL 241 24.5 — 5.55 - 14.6 —
5-FU/LV/BEV 249 34.1 0.019 8.77 0.0001 17.9 0.0081
Saltz et al (2008) FOLFOX or CAPOX 701 38 — 8.0 0.0023 19.9 0.077
XELOX-1/ NO16966 FOLFOX/CAPOX + BEV 699 38 0.99 9.4 21.3
Tol et al (2009) CAPOX + BEV 368 50 — 10.7 — 20.3 —
CAIRO 2 CAPOX + BEV + cetuximab 368 52.7 0.49 9.4 0.01 19.4 0.16
Hecht et al (2009) FOLFOX + BEV 410 48 — 11.4 HR: 1.27 24.5 HR: 1.43
PACCE FOLFOX + BEV + PAN 413 46 NS 10.0 (95% CI:
1.06–1.52)
19.4 (95% CI:
1.11–1.83)
Hecht et al (2009) FOLFIRI + BEV 115 40 — 11.7 HR: 1.19 20.5 HR: 1.42
PACCE FOLFIRI + BEV + PAN 115 43 NS 10.1 (95% CI:
0.79–1.79
20.7 (95% CI:
0.77–2.62)
Reinacher-Schick et al (2008)
a CAPOX + BEV 127 53 — 10.4 — 26.7 —
AIO 0604 CAPIRI + BEV 120 55 NR 12.1 0.27 Not
reached
0.55
Hecht et al (2009) FOLFOX 583 46 — 7.7 — 20.5 —
CONFIRM 1 FOLFOX + PTK/ZK 585 42 NS 9.1 0.108 21.4 0.260
Grothey et al (2008b)
BriTE
b
Chemotherapy + BEV (non-randomised
US cohort study)
1953 NR NR 9.9 NR 25.1 NR
Berry et al (2008)
(BEAT
b)
Chemotherapy + BEV (non-randomised
non-US cohort study)
1914 NR NR 10.8 NR 22.7 NR
Second line
Giantonio et al (2007) FOLFOX 291 8.6 — 4.7 — 10.8 —
ECOG E3200 FOLFOX/BEV (10mgkg
 1) 289 22.7 o0.0001 7.3 o0.0001 12.9 0.0011
BEV (10mgkg
 1) 243 3.3 2.7 10.2
Kohne et al (2007) FOLFOX 429 18 — 4.1 — 11.8 —
CONFIRM 2 FOLFOX + PTK/ZK 426 19 NS 5.6 0.026 12.1 0.511
Cunningham et al (2008)
a A. FOLFOXþBEV 66 27 7.8 B vs AN R —
HORIZON I B. FOLFOXþcediranib (low dose) 71 18 — 5.8 0.29 NR
C. FOLFOXþcediranib (high dose) 73 19 NR 7.2 C vs A 0.79 NR NS
Saltz et al (2007)
a Irinotecan/cetuximab/ BEV 43 37 — 7.3 — 14.5 —
BOND 2 Cetuximab/ BEV 40 20 NR 4.9 NR 11.4 NR
LV¼leucovorin; FOLFOX: oxaliplatin/infused 5-FU/LV; BEV¼bevacizumab; CAPOX: capecitabine/oxaliplatin; IFL¼irinotecan/bolus 5-FU/LV; FOLFIRI: irinotecan-infused 5-FU/
LV; CAPIRI: capecitabine/irinotecan; PAN¼panitumumab; NR¼not reported; NS¼Not significant; HR¼hazard ratio; CI¼confidence interval. The first treatment arm of each
study was the control arm. Unless stated, all bevacixumab was given at 2.5mgkg
 1 per week. All P-values were compared with control arms.
aRandomised phase II studies.
bObservational registry studies.
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survival compared with IFL alone (Hurwitz et al, 2005). Notably
this pivotal bevacizumab study only included patients with
performance status (PS) 0 or 1. Another randomised trial was
performed in patients deemed to be unsuitable for first
line irinotecan-based combination chemotherapy regimens
(Kabbinavar et al, 2005b). In addition, they were required to have
at least one of the following characteristics: age X65 years, PS 1 or
2, serum albumin p3.5gdl
 1 or prior radiotherapy to abdomen or
pelvis. In this study, patients were randomised to receive either
5-FU/LV/bevacizumab or 5-FU/LV/placebo. The addition to
bevacizumab to 5-FU/LV resulted in a non-significant prolonga-
tion of survival. To more reliably quantify the benefit of adding
bevacizumab to 5-FU/LV, the above studies were pooled
(Kabbinavar et al, 2005a). There was an improvement for 5-FU/
LV/bevacizumab over control group (5-FU/LV or IFL) in terms of
OS, PFS and ORR.
Most recently, a large RCT (NO16966) was published (Saltz et al,
2008). Although the addition of bevacizumab to oxaliplatin–
fluoropyrimidine chemotherapy significantly improved PFS com-
pared with oxaliplatin–fluoropymidines alone, no significant
differences were seen in terms of ORR and OS. The magnitude
of benefit was less than expected from previous studies. One of the
reasons cited for the relative small survival benefit for bevacizu-
mab in the NO16966 study was the fact that large proportion of
patients (71%) discontinued treatment due to non-progression
events (Saltz et al, 2008) with many patients stopping oxaliplatin/
fluoropyrimidines and bevacizumab due to adverse events. Similar
proportion (71%) of patients from the FOLFOX þ bevacizumab
control arm in PACCE study also stopped treatment due to non-
progression events (Hecht et al, 2009), whereas 64% of patients did
so in the German AIO study (Reinacher-Schick et al, 2008). With
preclinical data suggesting rapid tumour blood vessel regrowth
following cessation of VEGF inhibition (Mancuso et al, 2006),
one may advocate the continuation of bevacizumab alone until
disease progression in the event of cytotoxic drug-induced
adverse events. However, re-introduction of VEGF inhibition
resulted in the same degree of reduced tumour vasculature as
initial VEGF inhibition, suggesting much of the regrown tumour
vasculature was still VEGF-dependent (Mancuso et al, 2006).
Similar observations were also made clinically (Cacheux et al,
2008). There is currently no definitive direct clinical evi-
dence to support the necessity of continuing bevacizumab when
chemotherapy needs to be stopped due to adverse events. Some
preliminary published data support continuing bevacizumab
beyond disease progression when second and subsequent lines
of chemotherapy were instituted, suggesting a role of conti-
nued suppression of the VEGF pathway (Grothey et al, 2008b).
However, the improved survival seen with continuing beva-
cizumab beyond disease progression seen in this observa-
tional study might only reflect a fitter group of patients being
retreated with combination chemotherapy, rather than bevacizu-
mab-specific (Kopetz and Abbruzzese, 2009). Therefore, these
non-randomised data should be viewed as hypothesis gener-
ating and need confirmation in a randomised trial setting.
Currently South West Oncology Group 0600 Trial is testing
this hypothesis and until results from this RCT are available,
first line use of bevacizumab should be discontinued at the time
of disease progression.
Another large study evaluated bevacizumab in a second line
setting (Giantonio et al, 2007). In patients previously treated with
irinotecan and fluoropyrimidine, the addition of bevacizumab to
oxaliplatin-infused 5-FU/leucovorin (FOLFOX) significantly im-
proved ORR, PFS and OS compared with FOLFOX alone. However,
bevacizumab monotherapy was ineffective in this situation and
should not be used routinely.
Tyrosine kinase inhibitors (TK1s) targeting at least partly VEGF
have recently been shown to be effective in other solid tumours
(Demetri et al, 2006; Escudier et al, 2007; Motzer et al, 2007).
Several oral anti-angiogenesis inhibitors have also entered clinical
development in CRC. Among these, vatalanib underwent phase III
trial testing in both first and second line treatment. In both of
these studies, no improvement in efficacy was seen with adding
vatalanib to FOLFOX chemotherapy (Hecht et al, 2007; Kohne
et al, 2007).
EPIDERMAL GROWTH FACTOR RECEPTOR
The EGFR-signalling pathway regulates the processes involved in
cell differentiation, proliferation, migration, angiogenesis and
apoptosis, all of which become dysregulated in cancer cells.
Cetuximab is a chimeric monoclonal antibody that specifically
targets EGFR with high affinity. After the initial pivotal
randomised phase II BOND study which demonstrated the ability
of cetuximab to circumvent chemotherapy resistance (Cunning-
ham et al, 2004), a series of randomised phase II–III trials for
EGFR-targeted monoclonal antibodies (mAbs) have been reported.
Table 2 shows the results of these trials (Cunningham et al, 2004;
Jonker et al, 2007; Tejpar et al, 2007; Van Cutsem et al, 2007, 2009;
Borner et al, 2008; Ciuleanu et al, 2008; Heinemann et al, 2008;
Sobrero et al, 2008; Wilke et al, 2008; Bokemeyer et al, 2009; Hecht
et al, 2009). All these studies supported the biological activity of
cetuximab in advanced CRC. The benefit of adding cetuximab to
first line FOLFIRI in prolonging PFS was relatively small and no
improvement in OS results was seen (Van Cutsem et al, 2009). In
the second line setting, cetuximab/irintoecan significantly im-
proved ORR and PFS (Sobrero et al, 2008), but with the
commercial availability of cetuximab to patients in the irinotecan
control arm on disease progression during the trial, no benefits
were seen with OS, although other factors might have contributed
to the lack of OS improvement. Forty-seven percent of patients in
the control arm received subsequent cetuximab and had a median
survival of 13 months, identical to patients who were randomised
to irinotecan plus cetuximab and received subsequent treatment
without cetuximab (Sobrero et al, 2008). One must therefore
balance the adverse, but manageable effect of prolonged skin rash
with some improvement in remaining progression-free and
improvement in at least some domains of quality of life (QoL).
In a chemotherapy–refractory situation, cetuximab did show
statistically significant improved survival and QoL over best
supportive care (BSC) (Jonker et al, 2007), but the cost-
effectiveness of this approach will need to be carefully evaluated.
Notably, no crossover was allowed in the BSC arm to receive
cetuximab on disease progression.
Panitumumab, a fully human monoclonal antibody against
EGFR was also evaluated against BSC (Van Cutsem et al, 2007).
Although a significant improvement in PFS was seen with
panitumumab, a large proportion of patients (76%) in the BSC
arm crossed over to the panitumumab arm on disease progression
and precluded any OS benefit to be seen. Nevertheless, this
improvement in PFS led to the licensing of panitumumab by the
Food and Drug Administration in September 2006. In Europe, the
same data was originally rejected for licensing of panitumumab
within the European Union. However, with further data available
for K-ras (Kirsten rat sarcoma viral oncogene homologue)
mutation in this study (Amado et al, 2008), the licensed indication
for panitumumab within EU is treatment of patients with
metastatic colorectal carcinoma after failure of fluoropyrimidine-,
oxaliplatin-, and irinotecan-containing chemotherapy regimens
whose tumours contain non-mutated (wild-type) K-ras.
EGFR TKI currently has no role in advanced CRC with only two
randomised studies showing little clinical benefit (Rothenberg
et al, 2005; Santoro et al, 2008). Several phase II studies found little
additional benefit of EGFR TKI on a conventional chemotherapy
platform (Hofheinz et al, 2006; Chau et al, 2007; Gelibter et al,
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Stebbing et al, 2008). More importantly, excessive toxicities were
encountered in a number of these studies, especially with
irinotecan combinations. The lack of EGFR mutations in CRC
and supra-additive toxicity of EGFR TKI to chemotherapy
regimens may partly explain why development of EGFR TKI in
advanced CRC would be unlikely to be fruitful.
With encouraging results seen with individually targeting VEGF
and EGFR as successful treatment strategies in advanced CRC, it
would be logical to consider dual inhibition of angiogenesis and
EGFR with support from preclinical data (Ciardiello et al, 2004;
Tonra et al, 2006). The BOND-2 study showed encouraging results
with this approach (Saltz et al, 2007). Recruiting similar
irinotecan–refractory population to the original BOND study,
the BOND-2 study randomised patients between cetuximab plus
bevacizumab vs irinotecan, cetuximab plus bevacizumab. The
efficacy seen with dual inhibition of VEGF and EGFR in the BOND-
2 study had improved by 2- to 3-fold in ORR, PFS and OS
compared with BOND study, although BOND study had a much
larger sample size and this was a cross trial comparison.
However, two large phase III studies have been published
disputing the benefit of dual EGFR/VEGF inhibition in combina-
tion with chemotherapy (Hecht et al, 2009; Tol et al, 2009). In the
PACCE study, the addition of panitumumab to oxaliplatin-based
chemotherapy plus bevacizumab resulted in significantly inferior
PFS and OS compared with chemotherapy plus bevacizumab
(Hecht et al, 2009). A further study, CAIRO 2, also reported a
significantly worse PFS with the addition of cetuximab to
Table 2 Randomised studies evaluating epidermal growth factor receptor inhibitors in advanced colorectal cancer
Study Treatment arms
Number
of
patients
Response
rates
(%) P-value
Median
progression-free
survival
(months) P-value
Median
overall
survival
(months) P-value
First line
Van Cutsem et al (2009) FOLFIRI 599 38.7 — 8.0 — 18.6 —
CRYSTAL FOLFIRI + cetuximab 599 46.9 0.004 8.9 0.048 19.9 0.31
Bokemeyer et al (2009)
a FOLFOX 168 36 — 7.2 — NR NR
OPUS FOLFOX + cetuximab 169 46 0.064 7.2 0.62 NR
Borner et al (2008)
a CAPOX 37 14 — 5.8 — 16.5 —
SAKK CAPOX + cetuximab 37 41 NR 7.2 NR 20.5 NR
Heinemann et al (2008)
a CAPIRI +cetuximab 93 47 — 6.7 — NR —
German AIO CAPOX + cetuximab 92 48 NR 7.9 NR NR NR
Ciuleanu et al (2008)
a FOLFIRI +cetuximab 78 45 — 8.3 — 18.9 —
CECOG FOLFOX +cetuximab 77 43 NR 8.6 NS 17.4 NR
Hecht et al (2009) FOLFOX + BEV 410 48 — 11.4 HR: 1.27 24.5 HR: 1.43
PACCE FOLFOX + BEV +
PAN
413 46 NS 10.0 (95% CI:
1.06–1.52)
19.4 (95% CI:
1.11–1.83)
Hecht et al (2009) FOLFIRI + BEV 115 40 — 11.7 HR: 1.19 20.5 HR: 1.42
PACCE FOLFIRI + BEV + PAN 115 43 NS 10.1 (95% CI:
0.79–1.79)
20.7 (95% CI:
0.77–2.62)
Second line
Sobrero et al (2008) Irinotecan 650 4.2 o0.0001 2.6 o0.0001 9.99 0.7115
EPIC Irinotecan + cetuximab 648 16.4 4.0 10.71
Third and subsequent line
Jonker et al (2007) BSC 285 0 o0.001 1.8 o0.001 4.6 0.005
NCIC CO17 Cetuximab + BSC 287 8 1.9 6.1
Van Cutsem et al (2007) BSC 232 0 o0.0001 1.8 o0.0001 NR 0.81
Panitumumab + BSC 231 10 2 NR
Cunningham et al (2004) Cetuximab 111 10.8 0.0074 1.5 o0.001 6.9 0.48
BOND
a Irinotecan + cetuximab 218 22.9 4.1 4.8
Tejpar et al (2007)
EVEREST
a
Irinotecan + cetuximab
(standard dose)
45 16 — 3.9 — 10 —
Irinotecan + cetuximab
(escalating dose)
44 30 NR 4.8 NR 8.6 NR
Wilke et al (2008) MABEL
b Irinotecan + cetuximab 1147 20.1 — 3.2 — 9.2 —
LV¼leucovorin; FOLFOX¼oxaliplatin/infused 5-FU/LV; BEV¼bevacizumab; FOLFIRI¼irinotecan /infused 5-FU/LV; CAPOX¼capecitabine/oxaliplatin; BSC¼best supportive
care; PAN¼panitumumab; NR¼not reported; HR¼hazard ratio; CI¼confidence interval. The first treatment arm of each study was the control study. All P-values were
compared with control arms.
aRandomised phase II studies.
bObservational registry studies.
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OS benefit was seen with adding cetuximab in this study (Tol et al,
2009). The reasons behind this detrimental effect of adding EGFR
antibody to bevacizumab are currently unclear. Additional
toxicities were observed with adding panitumumab to bevacizu-
mab/oxaliplatin-based chemotherapy resulting in a lower dose
intensity in the PACCE study (Hecht et al, 2009). Pharmaco-
kinetic as well as pharmacodynamic interactions could occur
between bevacizumab and cetuximab/panitumumab. On the other
hand, bevacizumab-associated hypertension, a putative marker
for bevacizumab efficacy, was less frequent with CAPOX plus
bevacizumab/cetuximab in the CAIRO 2 study (Tol et al, 2009).
Both PACCE and CAIRO 2 did not pre-select patients with wild-
type K-ras tumours, the US Intergroup study, CALGB 80405, had
amended the entry criteria to exclude patients with K-ras
mutations and hopefully this would be able to answer definitely
whether synergy exists between cetuximab and bevacizumab in
wild-type K-ras patients.
Aside from combined inhibition of VEGF and EGFR, there are
other potential strategies to improve on the efficacy of EGFR-
targeted therapy. In a study with patients receiving cetuximab for
advanced CRC, 23% of patients were found to have HER2
fluorescent in-situ hybridisation positive disease (Finocchiaro
et al, 2007). Patients with HER2-positive disease had a significantly
worse TTP and OS compared to those with HER2-negative disease.
Dual targeting treatment is now available for EGFR and HER2
(Geyer et al, 2006) and this might be a strategy worth pursuing in
advanced CRC.
Preclinical evidence suggested that mAb and TKI against EGFR
might not have a completely overlapping mechanism of action and
synergistic actions had been observed for administering cetuximab
and gefitinib simultaneously in human xenograft models (Matar
et al, 2004). A phase I study has established that cetuximab and
gefitinib can be administered in combination at full individual
agent dose in patients who had failed chemotherapy treatment
(Baselga et al, 2006). Preliminary results showed an encouraging
50% response rate in CRC patients.
TOXICITIES FROM TARGETED AGENTS
Table 3 and 4 show toxicities seen with agents targeting VEGF and
EGFR respectively. Whereas bevacizumab in general does not
increase the toxicities from the cytotoxic agents, it does have
unique serious side effects, which thankfully are uncommon.
However, awareness about hypertension, thromboembolism,
bowel perforation and rarely reversible posterior leukoencephalo-
pathy syndrome should be raised to the patients’ primary care
physician and other allied health professionals for prompt
treatment of these complications. Cetuximab and panitumumab
do, however, increase incidences of some side effects (e.g.,
diarrhoea) from cytotoxic drugs. Nevertheless, integument-related
toxicities are very common and may adversely affect patients’ QoL
if used on a long-term basis, although oral minocycline may be
helpful in some patients (Scope et al, 2007). Furthermore, pre-
emptive skin treatment (using skin moisturisers, sunscreen,
topical steroid and oral doxycycline) starting before panitumu-
mab-based treatment has recently been shown to reduce skin
toxicity by 450% with improved QoL compared with reactive
skin treatment, that is, starting treatment after development of
skin rash (Lacouture et al, 2009). There is also a hint that
K-ras wild-type patients might experience more side effects
from cetuximab compared to those treated without cetuximab.
The increased toxicity from combining panitumumab and
bevacizumab is noteworthy (Hecht et al, 2009). However, the
CAIRO 2 study did not report any safety concern (Tol et al,
2009), further safety data are awaited from cetuximab plus
bevacizumab.
BIOMARKERS FOR EFFICACY AND TOXICITY
Until recently, the most consistent predictor for response and
survival to EGFR mAb is the development of skin rash. Multiple
RCTs showed a correlation between survival and severity of skin
reaction (Cunningham et al, 2004; Jonker et al, 2007; Van Cutsem
et al, 2007, 2009). Because no dose-limiting toxicity was observed
in phase I studies of cetuximab with the current recommended
dosing regimen, individualised dose titration based on the
occurrence and severity of skin rash may improve the effectiveness
of cetuximab treatment. EVEREST study randomized patients with
ograde 2 skin reaction after 3 weeks of cetuximab to either
continue on the same dose of cetuximab or escalate dose up to
500mgm
 2 (Tejpar et al, 2007). Although this study was small,
there was nearly a doubling of ORR (16% standard dose vs 30%
escalating dose). However, due to the small sample size, 95%
confidence interval for the ORR overlapped between the two arms.
Furthermore, PFS and OS did not show any improvement in dose
escalation of cetuximab.
However, skin rash could only be assessed after treatment had
been commenced. More than 90% of patients destined to develop
rash would only do so after 4 weeks of cetuximab (i.e. after four
infusions already) (Jonker et al, 2007). Other biomarkers that
could predict efficacy before commencing on cetuximab or
panitumumab would be more desirable. A number of RCTs
evaluating panitumumab/cetuximab has reported their data on a
K-ras analysable population. Table 5 shows the results of these
studies (Amado et al, 2008; Karapetis et al, 2008; Tejpar et al, 2008;
Van Cutsem et al, 2009; Bokemeyer et al, 2009; Hecht et al, 2009;
Tol et al, 2009). K-ras mutation occurred in about 35–43% of
patients. Patients with wild-type K-ras and treated with panitu-
mumab or cetuximab enjoyed generally longer PFS and better ORR
compared with those not treated by these antibodies, but those
patients with mutant K-ras did not derive any benefit from
panitumumab/cetuximab. As all of these studies reported K-ras
data as a retrospective subgroup analysis, no OS benefit has been
demonstrated yet in K-ras wild-type patients receiving chemo-
therapy plus cetuximab/panitumumab over those receiving
chemotherapy alone. This might be due to underpowered sample
sizes in these subgroup analyses. With these emerging data,
patients should be tested for K-ras mutation before commencing
on cetuximab/panitumumab treatment and only those with wild-
type tumours should be started on such treatment. Facilities to test
for K-ras mutation in routine clinical practise are lacking in many
institutions. Quality assurance for such testing would be required
and central reference laboratories with rapid turnover would be
essential, similar to HER 2 testing (Perez et al, 2006).
K-ras mutation appeared to have no impact on patients treated
with bevacizumab. The ORR, PFS and OS benefits of adding
bevacizumab to chemotherapy were independent to K-ras muta-
tion status (Hurwitz et al, 2009). Interestingly, despite patients
with K-ras wild-type tumours could benefit from cetuximab/
panitumumab, when these patients were treated with oxaliplatin-
based chemotherapy plus bevacizumab plus cetuximab/panitumu-
mab, no additional benefit was seen over chemotherapy plus
bevacizumab (Hecht et al, 2009; Tol et al, 2009). Indeed they
appeared to have worse OS outcome with panitumumab (Hecht
et al, 2009). For patients with K-ras mutant tumours, treatment
with CAPOX plus bevacizumab plus cetuximab resulted in worse
survival outcome (Tol et al, 2009), similar to other studies where
chemotherapy plus cetuximab had the worst outcome in K-ras
mutant patients (Van Cutsem et al, 2008; Bokemeyer et al, 2009).
Therefore, for K-ras mutant patients, it would appear to be
potentially harmful to treat them with EGFR-targeted therapy.
Further biomarkers have also been evaluated to predict
responsiveness to cetuximab/panitumumab. BRAF mutation had
been found to be mutually exclusive to K-ras mutation and BRAF
mutation was found in 11–14% of K-ras wild type patients
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K-ras wild-type tumours but harbouring BRAF mutations did
not show any responses to cetuximab/panitumumab and had
inferior survival compared to those without BRAF mutations
(Di Nicolantonio et al, 2008; Cappuzzo et al, 2008b). In another
retrospective study, nuclear factor kappa B positivity by immuno-
histochemistry also appeared to have worse ORR, PFS and OS in
irinotecan-refractory patients receiving irinotecan plus cetuximab
(Scartozzi et al, 2007), whereas patients with EGFR gene
amplification were more likely to respond to cetuximab/panitu-
mumab (Moroni et al, 2005; Lievre et al, 2006; Sartore-Bianchi
et al, 2007; Personeni et al, 2008; Cappuzzo et al, 2008a).
For conventional cytotoxics, a large number of studies has been
performed evaluating variations in genes associated with drug
metabolism and targets and the effects of these variations on
treatment outcome and toxicities. This has been systematically
reviewed (Funke et al, 2008). Most of these studies were small
(o200 patients), retrospective and non-randomised; included a
heterogeneous patient population and utilised a variety of
laboratory techniques and biological materials including primary
tumours, metastasis and peripheral blood. Few genetic variants
have therefore been shown to be unequivocally associated with
treatment outcome. Overall, the homozygous UGT1A1*28
insertion polymorphism was associated with increased risk of
irinotecan-related toxicities. XPD gene (ERCC 2) variations led to
differences in DNA-repair capability. Glutathione-S-transferases
(GST) are phase II metabolising enzymes involved in detoxifica-
tion of platinum compounds. GSTP1-105 mutations were asso-
ciated with improved outcome (Funke et al, 2008).
Recently, the largest published RCT in advanced CRC, FOCUS
(Seymour et al, 2007a), reported the first results of a nested
prospective search for biomarkers within the FOCUS study (Braun
et al, 2008). Topo 1, a molecular target of SN38 (active metabolite
of irinotecan) was found to be a predictive biomarker to irinotecan
therapy in the assessable 1313 patients. Patients with low Topo 1
did relatively well with first line 5-FU monotherapy, but did not
benefit in PFS or OS from adding irinotecan or oxaliplatin. With
increasing expression of Topo 1, the outcome with 5-FU alone was
worse, but addition of a second drug improved the treatment
outcome, with a major improvement in survival for the highest
expressing patients. This observation was seen with the addition of
either irinotecan or oxaliplatin, but the association with improved
survival was stronger with irinotecan. None of the other
biomarkers studied, including ERCC1, MLH1/MSH2, p53, MGMT,
COX-2 protein expression as assessed by tumour immunohisto-
chemistry or GST-P1, ABCB1, XRCC1, ERCC2, UGT1A1 germ-line
Table 3 Toxicities encountered during selected studies evaluating bevacizumab in advanced colorectal cancer
Study
Treatment
arms
Number
of evaluable
patients
Grade 3/4
hypertension
(%)
Venous
thrombosis
(%)
Arterial
thrombosis
(%)
Grade 3/4
bleeding
(%)
Grade 2-4
proteinuria
(%)
GI
perforation
(%)
Kabbinavar et al (2003) 5-FU/LV 35 0 6 3 0 NR NR
5-FU/LV/BEV (5mgkg
 1) 35 9 26 0 0 NR NR
5-FU/LV/BEV (10mgkg
 1) 32 25 6 6 9 NR NR
Hurwitz et al (2004) IFL 397 2 11.4 1 2.5 6.6 0
AVF 2107 IFL/BEV 393 11 12.5 3.3 3.1 3.9 1.5
5-FU/LV/BEV 109 6.4 9.2 4.6 6.4 1.8
a 0
Kabbinavar et al (2005b) 5-FU/LV 104 3 11 5 3 4 0
5-FU/LV/BEV 100 16 9 10 5 8 2
Kabbinavar et al (2005a) 5-FU/LV or IFL 237 3 9 3 2 4 0
5-FU/LV/BEV 244 16 10 5 5 9 1
Giantonio et al (2007) FOLFOX 285 1.8 2.5 0.4 0.4 0 0
ECOG E3200 FOLFOX/BEV (10mgkg
 1) 287 6.2 3.4 0.9 3.4 0.7 1
BEV (10mgkg
 1) 234 7.3 0.4 0.4 2.1 0 1.3
Saltz et al (2007) FOLFOX or CAPOX 675 1 5 1 1 NR o1
XELOX-1/NO16966 FOLFOX or CAPOX/BEV 694 4 8 2 2 o1 o1
Hecht et al (2009) FOLFOX + BEV 397 5 12 NR NR NR 0
PACCE FOLFOX + BEV +
panitumumab
4 0 7 4 1 3 N RN RN R 0
Hecht et al (2009) FOLFIRI + BEV 113 2 11 NR NR NR NR
PACCE FOLFIRI + BEV +
panitumumab
1 1 1 3 2 4 N RN RN R N R
Tol et al (2009) CAPOX + BEV 366 14.8 6.8 3.3 1.6 NR 0.3
CAIRO 2 CAPOX + BEV +
cetuximab
366 9.3 8.2 2.2 0.5 NR 1.6
Berry et al (2008) BEAT Chemotherapy + BEV 1914 5.3 NR 1.5 3.4 1.1 1.8
Grothey et al (2007) BriTE Chemotherapy + BEV 1953 NR NR 1.8 2.4 NR 1.8
aOnly grade 3 toxicity was reported. LV¼leucovorin; FOLFOX¼oxaliplatin/infused 5-FU/LV; BEV¼bevacizumab; CAPOX¼capecitabine/oxaliplatin; IFL¼irinotecan/bolus
5-FU/LV; NR¼not reported.
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found to be associated with treatment outcome from 5-FU plus
either irinotecan or oxaliplatin (Braun et al, 2008). Within the
same group of patients in FOCUS, those with KRAS and/or BRAF
mutation had a significantly worse OS compared to patients with
no mutation. However, treatment efficacy from oxaliplatin or
irinotecan was not impacted by the KRAS/BRAF mutation status
(Richman et al, 2008).
SHOULD ORAL FLUOROPYRIMIDINES SUBSTITUTE
INFUSED FLUOROURACIL IN ADVANCED CRC?
Only capecitabine has been evaluated as combination treatment
regimens in randomised phase III trials in conjunction with
oxaliplatin, irinotecan±bevacizumab. Such data are currently
lacking with UFT and S-1. Five phase III RCTs have been reported
to establish non-inferiority of CAPOX compared with FOLFOX.
Table 6 shows the efficacy results of these studies (Diaz-Rubio
et al, 2007; Ducreux et al, 2007; Porschen et al, 2007; Cassidy et al,
2008; Rothenberg et al, 2008). Two studies did not meet the
primary objective of demonstrating non-inferiority in PFS with
CAPOX compared with FOLFOX (Diaz-Rubio et al, 2007; Porschen
et al, 2007). In the third study (Ducreux et al, 2007), a rather
permissive non-inferiority margin was used with a primary end
point being ORR – a questionable primary efficacy end point for
first line advanced CRC trials in the modern era. However, the
largest study, NO16966 (a commercially sponsored study), did
clearly establish non-inferiority in PFS with CAPOX compared
with FOLFOX, although the convenience of capecitabine did come
with a price of nearly doubling of grade 3/4 diarrhoea (20%
CAPOX vs 11% FOLFOX) in the dose schedule used in NO16966
(Cassidy et al, 2008). A meta-analysis of the above studies plus two
further randomised phase II studies reported a significantly
reduced ORR with CAPOX compared with FOLFOX (Arkenau
et al, 2008). However, CAPOX was non-inferior in PFS and OS
compared with FOLFOX.
Two studies have also been reported comparing capecitabine/
irinotecan (CAPIRI) with FOLFIRI – both of which did not reach
their recruitment targets. In the first EORTC 40015 study,
recruitment was suspended after 85 patients (originally planned
recruitment n¼629) because of the frequent occurrence of grade
3/4 diarrhoea (CAPIRI 37% vs FOLFIRI 13%) and more fatal events
occurring in the CAPIRI arm (CAPIRI n¼6 vs FOLFIRI n¼2).
Five deaths in the CAPIRI arm and both deaths in the FOLFIRI
arm were considered to be treatment-related. PFS and OS were all
worse with CAPIRI compared with FOLFIRI (Kohne et al, 2008). In
the second study BICC-C (Fuchs et al, 2007), CAPIRI was
associated with a significantly worse PFS compared with FOLFIRI,
when associated with higher rates of severe vomiting, diarrhoea
and dehydration. In view of the toxicity concerns, further
enrolment into CAPIRI arm in this study was discontinued after
the first period of the study (pre-bevacizumab) with 430 patients
randomised. However, both the EORTC 40015 and BICC-C had
one further complicating factor – a second randomisation to either
celecoxib or placebo. Coxibs have been associated with an
increased risk of cardiovascular thrombotic events in colorectal
neoplasia (Solomon et al, 2005; Kerr et al, 2007). There might be
an interaction between celecoxib with CAPIRI that compromised
CAPIRI’s efficacy and increased its toxicity. A further large
randomised study (CAIRO) evaluating CAPIRI completed patient
recruitment (Koopman et al, 2007). CAPIRI treatment did result in
grade 3–4 diarrhoea incidence of 27%. A further randomised
study of CAPOX plus bevacizumab vs CAPIRI plus bevacizumab
using a lower dose of capecitabine and irinotecan resulted in a
more tolerable grade 3–4 rate of 16 (CAPOX) and 13% (CAPIRI)
respectively (Reinacher-Schick et al, 2008).
Taken together, when using an irinotecan-based regimen in the
treatment of first line metastatic CRC, FOLFIRI is the preferred
approach unless there is a clear contraindication to continuous
infusion 5-FU. Further development in alterative dosing schedule
of CAPIRI could provide a better efficacy and safety profile than
that used in these three published trials. When using an
oxaliplatin-based regimen, capecitabine could substitute infused
5-FU. However, the relative benefit/cost-effectiveness may also
depend on the health care system and reimbursement pattern of
individual countries (Mayer, 2007).
SHOULD WE USE SEQUENTIAL TREATMENT OR
FIRST LINE COMBINATION CHEMOTHERAPY?
In a pooled analysis of 11 phase III trials in CRC including 5768
patients (Grothey and Sargent, 2005), there was a strong
Table 4 Toxicities encountered during randomised studies evaluating EGFR antibodies in advanced colorectal cancer
Study Treatment arms
Number of
evaluable
patients
Grade 3/4
diarrhoea (%)
Grade 3/4
nausea +
vomiting (%)
Grade 3/4
hypo-magnesiumia
(%)
Grades
2–4 skin
reaction (%)
All grades
infusion
reaction (%)
CRYSTAL FOLFIRI 602 10.5 5.0 0.2
a 0.2 0
FOLFIRI + cetuximab 600 15.7 4.7 1.8
a 19.7 2.5
OPUS FOLFOX 168 7 NR 0 0.6 2
FOLFOX + cetuximab 170 8 NR 2 18 5
PACCE FOLFOX/BEV 397 13 7 0 1 NR
FOLFOX/BEV/PAN 407 24 13 4 36 NR
PACCE FOLFIRI/BEV 113 9 8 1 0 NR
FOLFIRI/BEV/PAN 111 28 13 5 38 NR
CAIRO2 CAPOX/BEV 366 19.1 16.7 NR 20.8 4.1
CAPOX/BEV/cetuximab 366 26 12.3 NR 39.1 4.9
EPIC Irinotecan 650 16.2 11.6 0.4 0.5 0.8
Irinotecan + cetuximab 648 28.8 11.7 3.3 8.2 1.4
BOND Cetuximab 115 1.7 4.3 NR 5.2 3.5
Irinotecan + cetuximab 212 21.2 7.1 NR 9.4 0
NCIC CO 17 BSC 274 NR 11 0 0.4 0
BSC + cetuximab 288 NR 11.2 5.8 11.8 4.5
PANITUMUMAB BSC 234 0 1 0 9 (all grades) 0
BSC + panitumumab 239 1 3 3 90 (all grades) 0
MABEL Irinotecan + cetuximab 1147 19.4 5.3 NR 13.3 12.7
aOnly 20% of patients had serum magnesium measurement. FOLFOX¼oxaliplatin/infused 5-FU/LV; BEV¼bevacizumab; FOLFIRI¼irinotecan/infused 5-FU/LV; BSC¼best
supportive care; PAN¼panitumumab; NR¼not reported.
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Study
No. of patients
evaluable for
K-ras mutation/No.
of patients in the
ITT study population
Proportion of
patients with
K-ras
mutations
Treatment
by mutation status
Response
rates (%) P-value
Median
progression-free
survival P-value
Median
overall
survival P-value
First line
Van Cutsem et al (2009) 540/1198 (45%) 35.6% mutant Wild type
CRYSTAL FOLFIRI 43.2 0.0025 8.7 months 0.02 21.0 months HR: 0.84
(95% CI: 0.64–1.11)
FOLFIRI +cetuximab 59.3 9.9 months 24.9 months
Mutant
FOLFIRI 40.2 0.46 8.1 months 0.75 17.7 months HR: 1.03
(95% CI: 0.74–1.44)
FOLFIRI +cetuximab 36.2 7.6 months 17.5 months
Bokemeyer et al (2009) 233/337 (69%) 42% mutant Wild type
OPUS FOLFOX 37 0.011 7.2 months 0.0163 NR NR
FOLFOX +cetuximab 61 7.7 months NR
Mutant
FOLFOX 49 0.106 8.6 months 0.0192 NR NR
FOLFOX +cetuximab 33 5.5 months NR
Hecht et al (2009) 865/1053 (82%) 40% mutant Wild type
PACCE FOLFOX +
bevacizumab
56 NR 11.5 months HR: 1.36 (95% CI:
1.04–1.77)
24.5 0.045
FOLFOX +
bevacizumab +
panitumumab
50 9.8 months 20.7
Mutant
FOLFOX +
bevacizumab
44 NR 11.0 months 19.3
FOLFOX +
bevacizumab +
panitumumab
47 10.4 months 19.3
Tol et al (2009) 528/736 (72%) 39.6% mutant Wild type
CAIRO 2 CAPOX + bevacizumab 50.0 0.06 10.6 months 0.030 22.4 months 0.64
CAPOX + bevacizumab
+cetuximab
61.4 10.5 months 21.8 months
Mutant
CAPOX + bevacizumab 59.2 0.03 12.5 months 0.003 24.9 months 0.03
CAPOX + bevacizumab
+cetuximab
45.9 8.1 months 17.2 months
Hecht et al (2009) 865/1053 (82%) 40% mutant Wild type
PACCE FOLFIRI + bevacizumab 48 NR 12.5 months NR 19.8 NR
FOLFIRI + bevacizumab
+ panitumumab
54 10.0 months NE
Mutant
FOLFIRI + bevacizumab 38 NR 11.9 months 20.5 months
FOLFIRI + bevacizumab
+ panitumumab
30 8.3 months 17.8 months
Subsequent lines
Tejpar et al (2008) 148/157 (94%) 39% mutant Wild type
EVEREST Irinotecan +cetuximab
(standard dose)
30.4 0.396 5.7 months for all
wild-type patients
0.014 (in favour of wild
type in standard dose)
NR NR
Irinotecan +cetuximab
(escalating dose)
41.9 NR
Mutant o0.0001
Irinotecan +cetuximab
(standard dose)
0 NR 2.7 months for all
mutant patients
(in favour of wild type
in escalating dose)
NR NR
Irinotecan +cetuximab
(escalating dose)
0N R
Amado et al (2008) 427/463 (92%) 43% mutant Wild type
Panitumumab 17 NR 12.3 weeks o0.0001 8.1 months NS
BSC 0 7.3 weeks 7.6 months
Mutant
Panitumumab 0 NR 7.4 weeks 0.99 4.9 months NS
BSC 0 7.3 weeks 4.4 months
Karapetis et al (2008) 394/572 (69%) 42.3% mutant Wild type
NCIC CO.17 Cetuximab 12.8 NR 3.7 months o0.001 9.5 months o0.00
BSC 0 1.9 months 4.8 months 1
Mutant
Cetuximab 1.2 NR 1.8 months 0.96 4.5 months 0.89
BSC 0 1.8 months 4.6 months
ITT¼intension to treat; FOLFOX¼oxaliplatin-infused 5-FU/LV; FOLFIRI¼irinotecan-infused 5-FU/LV; BSC¼best supportive care; NR¼not reported; NS¼not significant;
NE¼not estimable.
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treated with 5-FU/LV, irinotecan and oxaliplatin at some point in
their disease. However, combination doublet therapy was not
always beneficial in the first line treatment of advanced CRC.
Although this analysis was not a formal meta-analysis using
individual patient data, it gave a timely indication to clinicians of
the importance of having access to all three active drugs –
fluoropyrimidines, irinotecan and oxaliplatin in advanced CRC.
Several RCTs had attempted to determine whether upfront com-
bination chemotherapy offers any advantage over giving these agents
in a sequential manner. Table 7 shows the results of three studies
(Koopman et al, 2007; Seymour et al, 2007a; Cunningham et al, 2009).
FOCUS trial is the largest RCT conducted to date in advanced
CRC (Seymour et al, 2007a). 2135 patients were randomly allocated
into strategy (A) sequential single agent 5-FU/LV followed by
single agent irinotecan; strategy (B) single agent 5-FU/LV followed
by combinations with either FOLFIRI or FOLFOX and strategy (C)
first line combination treatment with FOLFIRI or FOLFOX and
then the reverse regimen on disease progression. Strategies B and
C produced very similar survival, both slightly better than strategy
A, but no significant OS differences were seen among all three
strategies (P40.01). Similar to other RCTs (Tournigand et al,
2004), comparisons of irinotecan vs oxaliplatin, whether used in
first line, second line combinations or at any time showed no
significant OS difference in FOCUS trial. However, median survival
in the FOCUS trial appeared to be lower than other contemporary
studies, possibly due to the fact that only patients with
unresectable metastasis were recruited and only 23% of patients
had received all three active drugs of fluorouracil, irinotecan and
oxaliplatin. Again similar to other trials (Hospers et al, 2006;
Cunningham et al, 2009), ORR and PFS for first line FOLFOX and
FOLFIRI were significantly better than for fluorouracil alone, but
this was achieved with the expense of greater toxicity. There
appeared to be no advantage or disadvantage in QoL associated
with first line combination treatment.
Another study (CAIRO) randomly allocated patients to sequen-
tial capecitabine followed by irinotecan followed by CAPOX
(sequential arm) or first line CAPIRI followed by second line
CAPOX (combination arm) (Koopman et al, 2007). Again
combination treatment did not significantly improve OS over
sequential treatment, despite an improvement in ORR and PFS
with first line combination treatment. Interestingly, the deteriora-
tion in QoL functioning was on average more for combination
treatment in all domains in this study. LIFE study randomly
allocated patients to sequential LV5FU2 followed by irinotecan
or FOLFOX followed by irinotecan. Upfront combination
FOLFOX significantly improved response rate and PFS, but
no improvement of OS was seen over sequential treatment
(Cunningham et al, 2009).
A fourth study addressed the same issue in the elderly or
physically unfit population (FOCUS 2) (Seymour et al, 2007b). The
study used a 2 2 factorial design to assess firstly whether
capecitabine gave better QoL improvement compared with 5-FU,
reserving oxaliplatin combination for second line treatment.
Second comparison assessed whether addition of oxaliplatin to
either capecitabine or 5-FU in first line setting would improve PFS
Table 6 Randomised trials of oxaliplatin-infused 5-FU/leucovorin vs oxaliplatin/capecitabine
Study
Treatment
arms
Number of
patients
Objective
response rates
(%)
Median PFS/
TTP (months)
Median overall
survival
(months) Comments
First line
Porschen et al (2007)
German AIO
FUFOX 234 54 8.0 18.8 Primary end point¼PFS
CAPOX 242 48 7.1 16.8 Non-inferiority margin for 95% CI
o1.29.
HR: 1.17; 95% CI: 0.96–1.43, therefore
11 end point not met
Diaz-Rubio et al (2007)
Spanish TTD
FUOX 174 46 9.5 20.8 Primary end point¼TTP
CAPOX 174 37 8.9 18.1 Non-inferiority margin for 95% CI
o1.27.
HR: 1.18; 95% CI: 0.9–1.5, therefore 11
end point not met
Ducreux et al (2007)
French
FOLFOX 6 150 46 9.3 20.5 Primary end point¼best response rate
CAPOX 156 42 8.8 19.9 Non-inferiority margin for 95% CI
o15%.
Difference in response rate¼4.7%
upper limit of 95% CI¼14.4%,
therefore 11 end point just met
Cassidy et al (2008)
XELOX -1
FOLFOX 4 1017 39 8.5 19.6 Primary end point¼PFS
CAPOX 1017 37 7.9 19.8 Non-inferiority margin for 97.5% CI
o 1.23.
HR: 1.05; 97.5% CI: 0.94–1.18,
therefore 11 end point met
Second line
Rothenberg et al (2008)
XELOX -2
FOLFOX 4 314 12.4 5.5 13.2 Primary end point¼PFS
CAPOX 313 15.3 5.1 12.7 Non-inferiority margin for 95% CI
o1.30.
HR: 1.03; 97.5% CI: 0.87–1.24,
therefore 11 end point met
FUFOX, FUOX and FOLFOX¼different dose schedules of oxaliplatin/infused 5-FU/LV; PFS¼progression free survival; TTP¼time to tumour progression; HR¼hazard ratio;
CI¼confidence interval.
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starting dose of 80% standard dose. With a median age of 75 and
30% of patients with PS 2, this represented an older and frailer
population compared with other RCTs. Only 30–50% of patients
escalated to a 100% dose. Addition of oxaliplatin increased ORR
(Po0.0001), but did not significantly improve PFS (P¼0.06) or OS
(P¼0.61). In this patient population, substituting 5-FU with
capecitabine did not result in any significant differences in PFS
or OS. Interestingly in some measures of QoL, capecitabine-
containing regimen was worse than infused 5-FU. Capecitabine
also led to significantly increased incidences of nausea, diarrhoea,
lethargy and hand foot syndrome.
Currently in patients with unresectable metastasis, it would be
reasonable to consider first line monotherapy to maintain QoL, but
these patients must be monitored closely during treatment in order
not to miss the therapeutic window for exposure to other active
agents. However, both FOCUS and CAIRO studies utilised
treatment strategies without bevacizumab and cetuximab and thus
support for sequential treatment might not apply for patients with
access to these biological agents. On the other hand, there have
been no RCT to demonstrate OS benefit to give combination
chemotherapy plus monoclonal antibody over monotherapy plus
monoclonal antibody in a sequential manner. For patients with
resectable metastasis and perhaps those with heavy tumour burden
or significant symptoms, they might benefit more with combi-
nation first line chemotherapy to achieve higher and more durable
treatment responses.
WHAT IS THE OPTIMAL DURATION OF TREATMENT?
Although the optimal duration of adjuvant chemotherapy has been
addressed in CRC (O’Connell et al, 1998; Chau et al, 2005; Andre
et al, 2007), randomised data are lacking in advanced CRC
comparing the two strategies of continuous treatment until disease
progression or defined treatment duration. The United Kingdom
Medical Research Council published a randomised study compar-
ing intermittent or continuous palliative first line chemotherapy
for 354 patients with advanced CRC (Maughan et al, 2003). No
survival differences were found between the two treatment
strategies, though intermittent therapy was associated with
reduced toxicity. Notably, despite being a principal intention of
the trial, only 66 (37%) patients randomly assigned to the
intermittent group was rechallenged with the same first line
chemotherapy.
With the advent of widespread first line use of oxaliplatin-based
chemotherapy, oxaliplatin-induced cumulative neuropathy is
becoming a significant clinical problem. It can cause substantial
impairment of patients’ QoL as well as potentially compromising
efficacy due to reduced dose intensity. Randomised trials have so
far suggested potential benefits of calcium/magnesium infusion,
glutamine and glutathione in preventing oxaliplatin-induced
peripheral neuropathy (Wolf et al, 2008), but few drugs are
effective to treat established peripheral neuropathy. One of the
strategies that had been tested in a phase III setting to address this
issue was the ‘stop and go’ strategy. The OPTIMOX 1 study
randomised 620 patients to FOLFOX 4 till disease progression or
FOLFOX 7 (high dose of oxaliplatin and omission of bolus 5-FU)
for 12 weeks followed by LV5FU2 followed by oxaliplatin
reintroduction at the time of disease progression (Tournigand
et al, 2006). Overall, no differences were seen in response rates,
durations of disease control or overall survival between the two
arms, but the incidence of neurotoxicity was markedly reduced in
the FOLFOX 7 stop and go arm during oxaliplatin omission phase
of LV5FU2, suggesting a novel way to reduce toxicity for
patients. However, large variations among treatment centres in
reintroducing oxaliplatin might have explained the lack of
efficacy differences between the two arms as oxaliplatin
reintroduction had a significant positive impact on survival
(de Gramont et al, 2007).
A further study from the United States followed similar trial
design of assessing intermittent oxaliplatin vs continuous
oxaliplatin in the FOLFOX plus bevacizumab regimen (Grothey
et al, 2008a). This study also assessed the use of calcium/
magnesium infusion in a 2 2 factorial design. However, this
study was discontinued early due to an unplanned interim anal-
ysis of ORR showing worse results with patients receiving
calcium/magnesium infusion based on data collected through
the clinical research organisation. These inferior results with
calcium/magnesium infusion were not confirmed subsequently by
either investigator-reported or centrally reviewed ORR. Interest-
ingly, in this study, intermittent oxaliplatin was associated with
a significant prolongation of time to treatment failure as well
as PFS.
Following on from the OPTIMOX study, a randomised phase II
study was performed evaluating the OPTIMOX 1 strategy vs
FOLFOX 7 for 3 months only and then reintroduced FOLFOX 7 on
disease progression (thus a complete chemotherapy-free period)
(Maindrault-Goebel et al, 2007), there was no significant
differences in OS, PFS, ORR or duration of disease control
between the two arms, although there was a trend towards a benefit
with continuous chemotherapy. However, this may simply be a
reflection that 3 months of initial chemotherapy were not sufficient
and patients should be treated for longer periods (at least 6
months) before contemplating a treatment break. Another
GISCAD study randomised 266 patients to either intermittent
FOLFIRI (alternating FOLFIRI for 2 months and stopping
chemotherapy for 2 months) or continuous FOLFIRI till disease
Table 7 Randomised studies evaluating combination vs sequential treatment in advanced colorectal cancer
Study Treatment arms
Number of
patients First line response rates P-value
Median progression-free
survival from first line
treatment (months) P-value
Median overall
survival
(months) P-value
Seymour et al (2007a,b)
FOCUS
Strategy A 5-FU/LV - irinotecan 710 28% (5-FU/LV) 6.3 (5-FU/LV) 13.9
Strategy B 5-FU/LV - FOLFIRI or
FOLFOX
356 (FOLFIRI)
356 (FOLFOX)
28% (5-FU/LV) o0.001
(strategy C vs A
or B)
6.3 (5-FU/LV) o0.001
(strategy C vs A
or B)
15.1 NS
Strategy C FOLFIRI - FOLFOX
FOLFOX - FOLFIRI
356 (FOLFIRI)
357 (FOLFOX)
49% (FOLFOX or FOLFIRI) 8.5 (FOLFOX or FOLFIRI) 15.9
Koopman et al (2007)
CAIRO
Strategy A capecitabine -
irinotecan - CAPOX
410 20% (capecitabine) o0.0001 5.8 (capecitabine) 0.0002 16.3 0.3281
Strategy B CAPIRI - CAPOX 410 41% (CAPIRI or CAPOX) 7.8 (CAPIRI or CAPOX) 17.4
Cunningham et al (2009)
LIFE
Strategy A 5-FU/LV - irinotecan 363 29.8% (5-FU/LV) o0.0001 5.9 (5-FU/LV) o0.0001 15.2 0.155
Strategy B FOLFOX - irintoecan 362 54.1% (FOLFOX) 7.9 (FOLFOX) 15.9
LV¼leucovorin, FOLFOX¼oxaliplatin/infused 5-FU/LV, FOLFIRI¼irinotecan/infused 5-FU/LV, CAPOX¼capecitabine/oxaliplatin, CAPIRI¼capecitabine/irinotecan, NR¼not
reported, NS¼non significant.
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significant differences in ORR, PFS or OS between the two
strategies. Interestingly, patients treated with intermittent FOLFIRI
had a reduced risk of venous thromboembolism – a complication
with significant impact on patients’ QoL (Mandala et al, 2009).
A large phase III COIN trial addressing this issue has finished
recruiting 2421 patients into a three arm comparison with one of
the arms being intermittent treatment schedule vs control
continuous treatment schedule.
For second line treatment, one study randomised patients to
stop after 6 months of irinotecan or continuous irinotecan until
disease progression (Lal et al, 2004). Again no survival differences
were seen between these two strategies, although only a small
proportion (17%) of patients was progression-free after 6 months
of irinotecan, thus eligible for randomisation. Nevertheless, there
was no detriment to QoL for those patients who continued
irinotecan after an appropriate dose reduction in the initial phase
of treatment.
There is currently no detrimental survival effect for treatment
for a defined duration (at least 6 months) followed by a treatment
break compared with continuous treatment until disease progres-
sion. Prolonged continuous treatment may be associated with side
effects such as venous thromboembolism.
HOW DO WE TREAT THE ELDERLY, POOR
PERFORMANCE STATUS OR ASYMPTOMATIC
PATIENTS?
Elderly patients represent an increasing challenge. Declining organ
reserve may lead to an increased risk and decreased tolerance to
chemotherapy-induced side effects. However, recent pooled
analyses on elderly patients (aged 70 or more) with both
oxaliplatin-based and irinotecan-based chemotherapy showed
similar benefit from chemotherapy in terms of ORR, PFS and OS
compared with those aged o70 years (Goldberg et al, 2006;
Folprecht et al, 2008). Toxicity was similar when treated with
irinotecan-based chemotherapy, but more neutropenia, thrombo-
cytopenia was seen in the elderly when treated with FOLFOX.
Caution needs to be exercised to extrapolate these data to routine
clinical practise, as patients enrolled into these RCTs were fit older
patients and only 0.9–2% of patients were octogenarians. Similar
efficacy and toxicity were observed when older patients were
treated with bevacizumab-based treatment compared with younger
patients (Kabbinavar et al, 2009).
There is often uncertainty of whether patients with poor PS
would benefit from the treatment to the same extent to patients
with better PS. In another pooled analysis of nine first line
chemotherapy RCTs (Sargent et al, 2009), patients with PS 2
had a significantly worse PFS and OS compared to those with
PS 0 or 1. However, the likelihood of benefiting from experimental
treatment was similar between different PS groups. Furthermore,
patients with PS 2 also benefited with similar magnitude
from combination therapy over monotherapy compared to
patients with PS 0 or 1. Patients with PS 2 did experience more
nausea or vomiting, but otherwise had no increase in other adverse
events. Any differential toxicity in experimental vs control
treatment was not PS-dependent. Once again, these data cannot
be extrapolated to patients with PS 3 or 4 who were excluded from
such RCTs and therefore should not be offered chemotherapy
routinely.
In conjunction with the previously mentioned FOCUS 2 study,
which recruited elderly or poor PS patients, sequential or
combination strategies are both reasonable in these patients and
there is no evidence that efficacy is compromised or toxicity more
pronounced in these groups of elderly or PS 2 patients.
For patients with unresectable but low volume, asymptomatic
disease, there is some controversy about whether treatment needs
to be initiated immediately or whether an expectant policy can be
adopted for a period of time. Whereas the original Nordic study
concluded that early treatment in asymptomatic patients with
advanced CRC prolonged survival, asymptomatic period and time
to progression (1992), a meta-analysis of two subsequent studies
conducted in Canada and Australasia did not show significant
improvement in survival and QoL to commence early treatment in
asymptomatic patients (Ackland et al, 2005). Notably, the latter two
studies terminated prematurely due to poor accrual. It is unlikely
further studies would be performed to address this issue. However,
biological agents as monotherapy with relatively fewer side effects to
conventional cytotoxic treatment might be considered to stabilise the
disease (Pessino et al, 2008) and delay the introduction of
combination cytotoxic drugs with biological agents.
WHAT ARE THE CURRENT CONTROVERSIES WITH
RESECTION OF COLORECTAL METASTASIS?
Aggressive surgical approaches to metastatic disease are increas-
ingly practised with a proportion of patients enjoying long-term
survival. Five-year survival rates of 30–40% are seen with
resection of liver metastasis (Fernandez et al, 2004), despite a
lack of randomised data to support surgery. Introduction of new
drugs such as oxaliplatin and more recently monoclonal antibodies
have allowed sufficient downsizing of ‘unresectable’ liver meta-
stases to convert them to resectable following therapy.
In patients with resectable liver metastasis, the role of peri-
operative chemotherapy is still controversial. The European
Organisation for Research and Treatment of Cancer (EORTC)
40983 study randomised 364 patients to either peri-operative
FOLFOX or surgery alone (Nordlinger et al, 2008). Ninety-two
percent of patients had 1–3 liver metastasis and 75% had 42 years
between original diagnosis and development of liver metastasis.
Three-year PFS benefit from peri-operative FOLFOX did not reach
the conventional level of significance in all randomised patients
(P¼0.058; absolute difference: 7.2%), although 3-year progres-
sion-free survival was significantly improved in those receiving
peri-operative FOLFOX in the eligible population (P¼0.041;
absolute difference in 3-year PFS: 8.1%) and in the resected
patients (P¼0.025; absolute difference in 3-year PFS: 9.2%).
For patients who are considered to have inoperable liver
metastasis, a proportion of patients would achieve sufficient
downsizing after a period of conversion chemotherapy to allow
liver resection. In one study, 13% of patients were converted from
unresectable to resectable after chemotherapy (Adam et al, 2004).
Although OS was significantly worse in this group of patients
(P¼0.01) compared with those who were primarily resectable, this
former group of initially unresectable patients still had a
respectable 5-year OS rate of 33%.
The rate of liver resection correlated significantly with the ORR
of neoadjuvant chemotherapy (Folprecht et al, 2005). FOLFOXIRI
(5-FU/LV/oxaliplatin/irinotecan) resulted in a higher response rate
compared with FOLFIRI (60 vs 34% respectively; Po0.0001)
(Falcone et al, 2007). This improved response rate led to an
increased rate of surgical resection of metastasis. R0 resection was
achieved in a higher proportion of patients receiving FOLFOXIRI,
which might have contributed to the significant improvement of
PFS and OS with FOLFOXIRI compared with FOLFIRI. The
addition of cetuximab to FOLFIRI also significantly improved ORR
and thus R0 resection of metastasis compared with FOLFIRI alone
(4.8 vs 1.7% respectively; P¼0.002) (Van Cutsem et al, 2009). This
improvement in ORR with cetuximab was even more pronounced
in the K-ras wild-type population (Van Cutsem et al, 2008). In the
subgroup of patients with liver metastasis only, R0 resection was
increased and PFS significantly improved when cetuximab was
added to FOLFIRI. Although bevacizumab did not significantly
improve ORR when added to oxaliplatin/fluoropyrimidine com-
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study, there was a numerical increase in the curative surgery rate
in the bevacizumab-containing arm (19.2 vs 12.9%), although this
was a post hoc analysis. Even in patients resistant to initial
chemotherapy, one study showed that subsequent addition of
cetuximab to chemotherapy induced a response and allowed 12%
of patients to proceed to surgery with a median OS of 20 months
(Adam et al, 2007) and no increase in peri-operative mortality.
Currently there is no universally agreed optimal conversion
chemotherapy before resection of liver metastasis. FOLFOXIRI or
chemotherapy plus cetuximab in K-ras wild-type patients repre-
sent attractive options.
Liver injury secondary to chemotherapeutic agents is increasingly
recognised. Hepatic vascular lesions could be seen more frequently
in patients receiving neoadjuvant oxaliplatin-based chemotherapy
(Aloia et al, 2006) leading to higher red blood transfusion
requirement. In addition, more prolonged neoadjuvant treatment
led to a higher rate of re-operation and a longer hospital stay (Aloia
et al, 2006). Pre-operative irinotecan was associated with steatohe-
patitis and patients with this liver injury had higher 90-day
mortality (Vauthey et al, 2006). Neoadjuvant cetuximab was not
found to be associated with specific pathological liver damage yet
(Adam et al, 2007). These studies highlighted the importance of
chemotherapy-induced damage on the non-tumour bearing liver – a
complication that needs to be carefully assessed in future studies.
Although lung metastasis is less common than liver involve-
ment, similar long-term survival has been observed after complete
resection with a 5-year survival rate of 48% in a recent systematic
review of 20 surgical retrospective series (Pfannschmidt et al,
2007). However, similar to liver resection, it would be difficult to
conduct a randomised trial against no resection nowadays. Similar
approach of neoadjuvant chemotherapy in liver metastasis may be
beneficial in CRC lung metastasis.
CONCLUSIONS
The addition of bevacizumab to chemotherapy improved the
efficacy over chemotherapy alone in both first and second line
settings, although the magnitude of benefit may not be as great
when a more optimal chemotherapy platform is used. Studies
performed thus far did not address conclusively whether
bevacizumab should be continued in subsequent lines of
treatment. Anti-angiogenesis TKI has not shown any additional
benefit over chemotherapy alone so far. Although some benefits
were seen with cetuximab in all settings of treating advanced CRC,
K-ras mutation status provides an important determinant of who
would not benefit from such treatment. Caution should be
exercised when combining anti-angiogenesis with anti-EGFR
strategy until further randomised data become available. In totality
of randomised evidence, capecitabine is non-inferior to intrave-
nous fluorouracil when combined with oxaliplatin, although not all
study results were consistent. On the other hand, the dose schedule
used in randomised trials of irinotecan plus capecitabine might be
too toxic, hampering the potential use of this combination. In
patients with extensive unresectable metastasis, a staged strategy of
a single agent followed by a combination treatment might be an
alternative to upfront combination treatment, whereas in patients
with resectable metastasis, a combination therapy with a high
response rate appears to be essential. Sequential or combination
strategies are both reasonable in elderly or PS 2 patients. There is
no evidence that the efficacy is compromised or toxicity more
pronounced in elderly or PS 2 patients. Currently the optimal
duration of treatment remains uncertain, but there does not
appear to be clearly detrimental effect to stop treatment after a
defined duration of at least 6 months.
Management of advanced colorectal cancer has become
increasingly complex with our expanding (and improved) array
of medical, radiation and surgical treatment. What is certain,
however, is that our patients are benefiting from this intense
research focusing on colorectal cancer.
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